Tag results:

induced pluripotent stem cells

Unlocking the Potential of Induced Pluripotent Stem Cells for Wound Healing: The Next Frontier of Regenerative Medicine

[Advances in Wound Care] Since the last decade iPSC has been revolutionizing the field of wound healing and skin tissue engineering. Despite the current progress, safety and heterogeneity among iPSC lines are still major hurdles in addition to the lack of large animal studies.

Resolving Cell State in iPSC-Derived Human Neural Samples with Multiplexed Fluorescence Imaging

[Communications Biology] Researchers applied PRobe-based Imaging for Sequential Multiplexing (PRISM) to facilitate multiplexed imaging with facile, rapid exchange of imaging probes to analyze iPSC-derived cortical and motor neuron cultures that were relevant to psychiatric and neurodegenerative disease models, using over ten protein targets.

Microglial Signaling Pathway Deficits Associated with the Patient Derived R47H TREM2 Variants Linked to AD Indicate Inability to Activate Inflammasome

[Scientific Reports] Apoptotic cell phagocytosis and soluble TREM2 shedding were unaltered, suggesting a disjoint between the pathways and the signaling cascades downstream of triggering receptor on myeloid cells 2 (TREM2) in R47H-expressing induced pluripotent stem cell-derived microglia (iPS-Mg), whilst metabolic deficits in glycolytic capacity and maximum respiration were reversed when R47H expressing iPS-Mg were exposed to phosphatidylserine+ expressing cells.

Differentiation of Human Induced Pluripotent Stem Cells to Authentic Macrophages Using a Defined, Serum-Free, Open-Source Medium

[Stem Cell Reports] Scientists described a defined, serum-free, open-source medium for the differentiation of iPSC-derived macrophages. This medium was equally capable of maintaining these cells compared with commercial alternatives.

Vita Therapeutics Raises $32 Million in Oversubscribed Series a Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat Muscular Dystrophies

[Vita Therapeutics] Vita Therapeutics announced the completion of an oversubscribed $32 million Series A. Vita’s lead therapy, VTA-100, is currently undergoing studies for the treatment of limb-girdle muscular dystrophy. It is designed to be an autologous treatment that combines gene correction and iPSC technology to help repair and replace muscle cells.

Neurodevelopmental Signatures of Narcotic and Neuropsychiatric Risk Factors in 3D Human-Derived Forebrain Organoids

[Molecular Psychiatry] Investigators utilized human induced pluripotent stem cells to generate reproducible organoids that recapitulate dorsal forebrain development including early corticogenesis.

Popular